GLP-1 Receptor Agonist Market Size, Share & Industry Analysis, By Drug (Semaglutide, Exenatide, Lixisenatide, Liraglutide, Dulaglutide, and Others), By Route of Administration (Oral and Parenteral), By Age Group (Pediatric and Adults), By Indication (Obesity, Diabetes, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2024

Estimated Year

2025

Forecast Period

2025-2032

Historical Period

2019-2023

Growth Rate

CAGR of 16.8% from 2025-2032

Unit

Value (USD Billion)

 Segmentation

By Drug

• Semaglutide
• Exenatide
• Lixisenatide
• Liraglutide 
• Dulaglutide
• Others

By Route of Administration

• Oral
• Parenteral

By Age Group

• Pediatric
• Adults

By Indication

• Diabetes
• Obesity
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa